Fri, Jul 25, 2014, 3:45 PM EDT - U.S. Markets close in 15 mins.


% | $
Click the to save as a favorite.

Celldex Therapeutics, Inc. Message Board

  • weightbayou weightbayou Dec 14, 2013 7:37 PM Flag

    Any thoughts on ARRY?

    At $5 per share it seems cheap. Thanks in advance.

    SortNewest  |  Oldest  |  Most Replied Expand all replies
    • Wght, I like arry molecues but not their efficacy. Every product I see them hit has some huge potential but they seem to hit some bumps in the road. The anti inflammatory products look interesting and if those prove fruitful it could be a steal. The problem is no one is running after the asthma to take it to the clinical and the pain drug shows some good data but it shows QT prolongation which is usually the kiss of death for chronic drugs unless the doseage if off the charts. The oncology products are licensed everywhere and could be fruitful and 520 does look very interesting. Its such a dog and pony show pipeline its hard to tell to be honest it could get taken out easily for over a billion or so if the products progress but it could also be well over 10 billion if the molecues show efficacy and that is where they continue to be more bark than bite. They do have some very interesting platform science and think its worth nippling at and for a long term hold. If you are wanting a very interesting 3 dollar stock for a long term hold I would look at Kalobiotherapeutics. The asthma drug they have looks very interesting and heading into phase 3 next year. The EPHRIN anti body are probably going to be very good products and they are going to expand that to two more indications next year. Its early for them though and they are at 52 week low so it may be worth picking up a few hundred shares for a long term hold. Overall though Arry and KBIO are both small mid term buys and long long holds both about 18 months but Arry will some data coming very soon.

13.50-0.57(-4.05%)3:44 PMEDT

Trending Tickers

Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.